Navigation Links
CoLucid Appoints Thomas P. Mathers as Chief Executive Officer
Date:7/15/2011

DURHAM, N.C., July 15, 2011 /PRNewswire-iReach/ -- CoLucid Pharmaceuticals, Inc., a privately held biopharmaceutical company, announced today the appointment of Thomas P. Mathers, 44, as Chief Executive Officer.

Mr. Mathers has more than 19 years of executive management, sales and marketing experience in the life sciences and medical device industry. He also serves on the Board of Directors for the Biotechnology Industry Organization (BIO), and as chairman of Declion Pharmaceuticals, a company which he co-founded. Prior to CoLucid, he served as president and CEO of Peptimmune, Inc. from 2003 to 2011. Founding CEO, James F. White, Ph.D. will continue his involvement with CoLucid as scientific director.

"Tom has extensive leadership skills and brings valuable strategic, operational and transactional experience to our team at a key inflection point in the company's  growth and development," said Art Pappas, Chairman of the Board of Directors, and managing partner at Pappas Ventures. "Tom will lead the CoLucid team in formulating our phase 3 development and commercialization plans for lasmiditan," he added.

During his career, Mr. Mathers has also held positions as president and CEO of Cell Based Delivery; vice president and general manager of Cardion AG; vice president of Strategic Development at Genzyme; and management positions at Snowden-Pencer and Pfizer, Inc. He holds several patents and patents pending and earned his BS in Engineering from the United States Military Academy at West Point, where he was a Dean's List student and three-year starter on the football team as a defensive end. From 1988 to 1991 he served as captain in the United States Army and was awarded several medals for his services as an AH-64 Apache helicopter pilot in the Gulf War in the XVIII Airborne Corps.

"I am excited to join the CoLucid team and complete the development of lasmiditan, our breakthrough first in class treatment for acute migraine. This is an area of significant unmet need since many of the currently approved therapies have unwanted side effects and are contraindicated in some patients," said Mr. Mathers.

About CoLucid Pharmaceuticals, Inc.

CoLucid was founded in August 2005 by Pappas Ventures to advance innovative drug candidates with the potential to provide safe and effective treatment for central nervous system (CNS) disorders. The company's investors include Pappas Ventures, Domain Associates, Care Capital, Pearl Street Venture Funds and Triathlon Medical Ventures. The company's pipeline includes lasmiditan (COL-144), a novel treatment for migraine headache, and a conjugated stigmine platform that has generated a series of preclinical candidates for the treatment of sleep/wake disorders, chronic pain, Alzheimer's disease and psychiatric disorders. For more information, please visit CoLucid at www.colucid.com.

Media Contact: info@colucid.com


'/>"/>
SOURCE CoLucid Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Regulus Therapeutics Appoints Gregory Hannon, Ph.D. to Scientific Advisory Board
2. GenturaDx Appoints Senior Vice President of Research & Development
3. H. D. Smith Appoints Mark de Bruin Corporate Vice President Managed Care
4. OncoSec Medical Appoints Engineering Leader
5. Tris Pharma Appoints Vice President of Human Resources
6. Cepheid Appoints Vice President of Infectious Disease Research & Development
7. InstantLabs Appoints Dr. Neil Sharma as Director of Product Development
8. Hotspur Technologies Appoints Fred Khosravi Chairman of the Board
9. Ampio Pharmaceuticals, Inc. Appoints New Independent Director
10. TetraLogic Appoints Jonathan B. Lloyd Jones as Chief Financial Officer and Vice President Corporate Development
11. Kendle Appoints Pierre Geoffroy, MD, CM, MSc, FCFP Vice President, Early Stage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... -- According to the Centers for Disease Control and Prevention (CDC), influenza ... Care is helping communities across Massachusetts , ... no-cost* flu shots through the end of the month. *Some ... ... flu shot is by the end of October, according to the Centers ...
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
(Date:10/2/2017)... The Rebound mobile app is poised to become a vital ... prescription drug addiction. The app empowers users to develop an ... their dosage in a safe, controlled manner while maximizing well-being. ... 100,000 people to sign up will enjoy 3 months of ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... , ... October 13, 2017 , ... Ellevate Network, the ... business to advocate for action towards gender equality at their inaugural Summit in New ... the globe, and reached a social audience of over 3 million. To watch the ...
(Date:10/13/2017)... ... , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has ... least understood books in the Holy Scriptures, Revelation. The Book of Revelation paints a ... centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins says that ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Software Development, has been awarded a contract by the Center for Medicare and ... aims to accelerate the enterprise use of Agile methodologies in a consistent and ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history of ... Brink” is the creation of published author, William Nowers. Captain Nowers and his ... veteran, he spent thirty years in the Navy. Following his career as a ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco dentists, ... cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated to ... breathing. Oral appliances can offer significant relief to about 75 percent of people ...
Breaking Medicine News(10 mins):